MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 885 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
SOS1-IN-15
CAS:<p>SOS1-IN-15 is an orally active and potent SOS1 inhibitor with potential antitumor activity.SOS1-IN-15 is used in the study of colon cancer.</p>Formula:C28H27F3N6O2Purity:98.32%Color and Shape:SolidMolecular weight:536.548JNK-IN-11
CAS:<p>JNK-IN-11 inhibits JNK1/2/3 (IC50: 2.2/21.4/1.8 μM); promising for Alzheimer's/Parkinson's research.</p>Formula:C12H11NO3S2Purity:98.82%Color and Shape:SolidMolecular weight:281.35GSK2008607
CAS:<p>GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.</p>Formula:C31H28F3N7O3S2Purity:99.36%Color and Shape:SolidMolecular weight:667.72RAF mutant-IN-1
CAS:<p>RAF mutant-IN-1 is an inhibitor of RAF kinase(IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively).</p>Formula:C23H18Cl3FN6O2SPurity:98%Color and Shape:SolidMolecular weight:567.85ERK Inhibitor II (Negative control)
CAS:<p>ERK Inhibitor II, a control, blocks ERK and insulin receptor activation, aiding diabetes research.</p>Formula:C18H12N6OColor and Shape:SolidMolecular weight:328.33SOS1-IN-14
CAS:<p>SOS1-IN-14 是选择性的、有效的、口服具有活力的 SOS1 抑制剂 (IC50: 3.9 nM)。SOS1-IN-14 能够利用 P-糖蛋白介导的外排机制在肠道内被吸收。SOS1-IN-14 能够用于 KRAS 突变的癌症的研究，且抑瘤效果比 BI-3406 好。</p>Formula:C29H29F3N6O2Color and Shape:SolidMolecular weight:550.57p38-α MAPK-IN-1
CAS:<p>p38-α MAPK-IN-1 is a MAPK14 (p38-α) inhibitor with IC50 of 2300 nM and 5500 nM in EFC displacement assay and HTRF assay,respectively.</p>Formula:C27H35N5O3Purity:99.93%Color and Shape:SolidMolecular weight:477.6AZD4747
CAS:<p>AZD4747 is an inhibitor of the mutant GTPase KRASG12C that hasial antitumor activity for the study of pancreatic and colorectal adenocarcinoma.</p>Formula:C24H22ClFN2O3Purity:99.36%Color and Shape:SolidMolecular weight:440.89KRAS G12C inhibitor 14
CAS:<p>KRAS G12C inhibitor 14 is a potent KRAS G12C inhibitor with an IC 50 of 18 nM [1].</p>Formula:C24H19ClF2N4O3Purity:98%Color and Shape:SolidMolecular weight:484.88SOS1-IN-4
CAS:<p>SOS1-IN-4 is a potent inhibitor of SOS1 (IC50: 56 nM) and can be used in the study of KRAS-C12C/SOS1 interactions.</p>Formula:C24H29F2N4O2PColor and Shape:SolidMolecular weight:474.48L 731734
CAS:<p>L 731734 is a farnesyltransferase inhibitor.</p>Formula:C19H38N4O3SColor and Shape:SolidMolecular weight:402.6KRAS G12C inhibitor 30
CAS:<p>KRAS G12C inhibitor 30 is an inhibitor of KRAS G12C and can be used to study cancer.</p>Formula:C25H22ClFN6O3Color and Shape:SolidMolecular weight:508.93Pan-RAF kinase inhibitor 1
CAS:<p>Potent Pan-RAF inhibitor 1 targets RAF/MAPK pathway, curbing RAS-mutated cancer cell growth. (Patent WO2021110141A1, compound 16B)</p>Formula:C26H24F3N3O4Color and Shape:SolidMolecular weight:499.48KRAS G12C inhibitor 13
CAS:<p>KRAS G12C inhibitor 13 is a KRAS G12C inhibitor .</p>Formula:C40H46F3N7O4Purity:98%Color and Shape:SolidMolecular weight:745.83RPR203494
CAS:<p>RPR203494 is a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.</p>Formula:C26H29FN6O4Color and Shape:SolidMolecular weight:508.54HPK1-IN-37
CAS:<p>HPK1-IN-37 (compound A85), with an IC50 value of 3.7 nM, is a potent inhibitor of HPK1.</p>Formula:C27H35N7O4Color and Shape:SolidMolecular weight:521.61PROTAC KRAS G12C degrader-3
CAS:<p>PROTAC KRAS G12C Degrader-3 (Comp 283) serves as a potent degrader of KRAS G12C, utilized in cancer research [1].</p>Formula:C63H75ClN14O6Purity:98%Color and Shape:SolidMolecular weight:1159.81ERK1/2 inhibitor 8
CAS:<p>ERK1/2 inhibitor 8 is a potent inhibitor of ERK that acts on ERK2 (IC50: 0.48 nM).</p>Formula:C23H20ClN7O2SColor and Shape:SolidMolecular weight:493.97KRAS G12C inhibitor 35
CAS:<p>KRAS G12C inhibitor 35 targets KRAS G12C in cancer research (CN112920183A, compound 3).</p>Formula:C31H27ClF2N6O3Color and Shape:SolidMolecular weight:605.03CMP3a
CAS:<p>CMP3a, a NEK2 inhibitor, hinders GBM in mice and enhances radiotherapy by disrupting EZH2.</p>Formula:C28H27F3N6O2SColor and Shape:SolidMolecular weight:568.61Deltasonamide 1
CAS:<p>Deltasonamide is a potent and selective inhibitor of PDE6δ‐KRas.</p>Formula:C30H39ClN6O4S2Color and Shape:SolidMolecular weight:647.25(aS)-PH-797804
CAS:<p>(aS)-PH-797804 is a selective inhibitor of p38 MAPK, demonstrating inhibitory concentration (IC50) values of 26 nM for p38α and 102 nM for p38β. This compound exhibits anti-inflammatory activity [1] [2].</p>Formula:C22H19BrF2N2O3Color and Shape:SolidMolecular weight:477.3AMG-548 hydrochloride (864249-60-5 free base)
<p>AMG-548 hydrochloride is an orally active and selective p38α inhibitor (Ki: 0.5 nM) and shows slightly selective over p38β (Ki: 36 nM) and >1000 fold selective</p>Formula:C29H28ClN5OPurity:98%Color and Shape:SolidMolecular weight:498.02KRAS G12C inhibitor 49
CAS:<p>KRAS G12C inhibitor 49 is an orally active KRAS G12C inhibitor that exhibits antitumour effects.</p>Formula:C31H31ClN6O3Color and Shape:SolidMolecular weight:571.07JNK3 inhibitor-3
CAS:<p>JNK3 Inhibitor-3 selectively blocks JNK3 (>4.1 nM), crosses the blood-brain barrier, is orally active, and improves memory in dementia mice.</p>Formula:C26H25N7O2Purity:98%Color and Shape:SolidMolecular weight:467.52MEK-IN-6 hydrate
CAS:<p>MEK-IN-6 hydrate (compound 69), a MEK inhibitor, exhibits an IC50 value of 2 nM in A375 cells [1].</p>Formula:C18H22FN3O5SPurity:98%Color and Shape:SolidMolecular weight:411.45MEK-IN-6
CAS:<p>MEK-IN-6 (Example 69), a potent MEK inhibitor, effectively inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells, with an IC50 of 2 nM, making it</p>Formula:C18H20FN3O4SPurity:98%Color and Shape:SolidMolecular weight:393.43SOS1-IN-7
CAS:<p>SOS1-IN-7 (compound 18-p1) is a potent inhibitor of SOS1 and acts on SOS1-G12D (IC50: 20 nM) and SOS1-G12V (IC50: 67 nM).</p>Formula:C23H25F3N4O3Color and Shape:SolidMolecular weight:462.46KRas G12C inhibitor 1
CAS:<p>KRas G12C inhibitor 1 is a compound that inhibits KRas G12C.</p>Formula:C31H38N6O3Purity:98%Color and Shape:SolidMolecular weight:542.67TNIK&MAP4K4-IN-1
CAS:<p>TNIK&MAP4K4-IN-1 (compound A-39) is a potent dual inhibitor targeting TNIK and MAP4K4/HGK, exhibiting IC50 values of 1.29 nM and <10 nM, respectively, in human</p>Formula:C25H23FN4O3Color and Shape:SolidMolecular weight:446.47KRAS G12C inhibitor 34
CAS:<p>KRAS G12C inhibitor 34 is an inhibitor of KRAS G12C that can be used to study cancer research.</p>Formula:C32H32ClN5O3Color and Shape:SolidMolecular weight:570.08KRAS G12C inhibitor 41
CAS:<p>KRAS G12C inhibitor 41 targets a key signaling protein, potentially aiding cancer research.</p>Formula:C36H37ClFN9O2Color and Shape:SolidMolecular weight:682.19Uplarafenib
CAS:<p>Uplarafenib (B-Raf IN 10), a potent BRAF inhibitor (IC50: 50-100 nM), exhibits antitumor effects on solid cancers.</p>Formula:C22H21F3N4O4SPurity:99.85%Color and Shape:SolidMolecular weight:494.49SOS1-IN-13
CAS:<p>SOS1-IN-13 inhibits SOS1 (IC50: 6.5 nM) and pERK (327 nM); potential in cancer research.</p>Formula:C21H22F3N3O2Color and Shape:SolidMolecular weight:405.41p38 Kinase inhibitor 4
CAS:<p>Compound 135, also known as p38 Kinase Inhibitor 4, is a potent inhibitor of p38 [1].</p>Formula:C12H9Cl2N3OPurity:98%Color and Shape:SolidMolecular weight:282.13KRAS G12C inhibitor 5
CAS:<p>KRAS G12C inhibitor 5 is a KRas G12C inhibitor.</p>Formula:C32H37N7O2Purity:98%Color and Shape:SolidMolecular weight:551.68KRAS G12C inhibitor 21
CAS:<p>KRAS G12C inhibitor 21 is a KRAS G12C inhibitor.</p>Formula:C34H30ClN3O4Color and Shape:SolidMolecular weight:580.07pan-KRAS-IN-4
CAS:<p>Pan-KRAS-IN-4 (compound 5) is a potent KRAS inhibitor, demonstrating IC50 values of 0.37 nM for Kras G12C and 0.19 nM for Kras G12V [1].</p>Formula:C36H34F2N6O3Purity:98%Color and Shape:SolidMolecular weight:636.69Ras inhibitor 134
CAS:<p>Ras inhibitor 134 can be used in studies about Ras.</p>Formula:C23H21ClFN5O3Color and Shape:SoildMolecular weight:469.9JNK3 inhibitor-1
CAS:<p>JNK3 inhibitor-1: potent, selective, IC50 of 0.005 μM, orally bioavailable, brain-penetrant.</p>Formula:C21H17ClFN5O2SColor and Shape:SolidMolecular weight:457.91KRAS G12C inhibitor 51
CAS:<p>KRAS G12C inhibitor 51 is a KRAS G12C inhibitor.</p>Formula:C33H35FN6O3Color and Shape:SolidMolecular weight:582.67SOS1-IN-8
CAS:<p>SOS1-IN-8 is an inhibitor of SOS1 and acts on SOS1-G12D (IC50: 11.6 nM) and SOS1-G12V (IC50: 40.7 nM).</p>Formula:C24H26F3N3O4Color and Shape:SolidMolecular weight:477.48ERK1/2 inhibitor 7
CAS:<p>ERK1/2 inhibitor 7 is a potent inhibitor of ERK, acting on ERK2 (IC50: 0.94 nM).</p>Formula:C23H22FN7OSColor and Shape:SolidMolecular weight:463.53SOS1-IN-16
CAS:<p>SOS1-IN-16 (Comp 54) serves as a selective SOS1 inhibitor exhibiting an IC50 value of 7.2 nM and demonstrates inhibitory activity against CYP3A4 with an IC50 of</p>Formula:C30H31F3N4O3Purity:98%Color and Shape:SolidMolecular weight:552.59HPK1-IN-10
CAS:<p>HPK1-IN-10 inhibits HPK1, a MAP4K kinase from progenitor cells, with potential in treating HPK1 diseases, detailed in patent WO2021213317A1.</p>Formula:C31H34N6O2Color and Shape:SolidMolecular weight:522.64SOS1/KRAS-IN-1
CAS:<p>SOS1/KRAS-IN-1 (Compound 2) serves as an inhibitor of SOS1/KRAS, with potential application in the study of diseases mediated by SOS1/KRAS [1].</p>Formula:C24H26F3N5OPurity:98%Color and Shape:SolidMolecular weight:457.49KRAS inhibitor-18
CAS:<p>KRAS inhibitor-18 targets KRAS G12C; IC50: 4.74 μM. Inhibits p-ERK in cancer cells. Promising for pancreatic, colorectal, lung cancer research.</p>Formula:C20H15ClF3N3O2SColor and Shape:SolidMolecular weight:453.87GNE 220 hydrochloride
CAS:<p>GNE 220 (hydrochloride) is a potent and selective inhibitor of MAP4K4 (IC50: 7 nM).</p>Formula:C25H27ClN8Color and Shape:SolidMolecular weight:474.99SKF-86002 dihydrochloride
CAS:<p>p38 MAP kinase inhibitor</p>Formula:C16H14Cl2FN3SPurity:98%Color and Shape:SolidMolecular weight:370.27K-Ras G12C-IN-1
CAS:<p>K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C.</p>Formula:C22H23Cl2N3O3Color and Shape:SolidMolecular weight:448.34KRAS G12C inhibitor 25
CAS:<p>KRAS G12C inhibitor 25 blocks SOS1-mediated GDP/GTP swap in KRAS-G12C mutants; IC50: 0.48 nM (WO2021216770A1, comp. 3).</p>Formula:C32H41N7O2Color and Shape:SolidMolecular weight:555.71B-Raf IN 5
CAS:<p>B-Raf IN 5 is a potent inhibitor of the protein kinase B-Raf (IC50: 2.0 nM). B-Raf IN 5 resists rapid metabolism and does not bind to the secondary target PXR.</p>Formula:C23H18ClF3N6O3S2Color and Shape:SolidMolecular weight:583.01KRAS inhibitor-12
CAS:<p>KRAS inhibitor-12 blocks KRAS G12C (IC50: 0.537 μM) and p-ERK in cancer cells; promising for pancreatic, colorectal, lung cancer study.</p>Formula:C19H16Cl2FN5OSColor and Shape:SolidMolecular weight:452.33HPK1-IN-33
CAS:<p>HPK1-IN-33 inhibits HPK1 with 1.7 nM potency, reduces IL-2 in Jurkat cells with 286 nM EC50, and is less effective in HPK1 KO cells.</p>Formula:C18H16ClFN6Color and Shape:SolidMolecular weight:370.81KRAS G12C inhibitor 53
CAS:<p>KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.</p>Formula:C21H14ClF2N5O2Color and Shape:SolidMolecular weight:441.82HPK1-IN-11
CAS:<p>HPK1-IN-11 is a potent HPK1 inhibitor. HPK1-IN-11 has potential for the study of HPK1-related diseases.</p>Formula:C27H25N5O2Color and Shape:SolidMolecular weight:451.52pan-KRAS-IN-3
CAS:<p>Pan-KRAS-IN-3 (Example 84) is a pan-KRAS inhibitor suitable for cancer research [1].</p>Formula:C33H32F3N5O2Purity:98%Color and Shape:SolidMolecular weight:587.63SB 203580 sulfone
CAS:<p>SB 203580 sulfone, an analog of the p38 MAP kinase inhibitor SB 203580, inhibits IL-1 production in monocytes and binds competitively with CSAID binding proteins (CSBP), inhibiting stress response signaling. It exhibits an IC50 of 0.2 μM for IL-1 inhibition and 0.03 μM for CSBP-mediated signaling inhibition [1].</p>Formula:C21H16FN3O2SColor and Shape:SolidMolecular weight:393.43AZ-TAK1
CAS:<p>"AZ-Tak1 inhibits TAK1 kinase (IC50=0.009mM), reduces p38/ERK levels, and induces apoptosis in Mino, SP53, Jeko cells with increasing efficacy at 0.1-0.5mM."</p>Formula:C25H28FN7O2Color and Shape:SolidMolecular weight:477.53AMG-548 dihydrochloride (864249-60-5 free base)
<p>AMG-548 dihydrochloride: oral p38α inhibitor, Ki: 0.5 nM; less so for p38β, Ki: 36 nM; >> p38γ/δ; blocks LPS-induced TNFα, IC50: 3 nM.</p>Formula:C29H29Cl2N5OPurity:98%Color and Shape:SolidMolecular weight:534.48HPK1-IN-35
CAS:<p>HPK1-IN-35 is a potent, selective inhibitor of HPK1, demonstrating an IC50 value of 3.5 nM.</p>Formula:C30H32N8O3SColor and Shape:SolidMolecular weight:584.69Rac1-IN-3
CAS:<p>Rac1-IN-3 (Compound 2) is a Rac1 inhibitor exhibiting an inhibitory concentration 50 (IC50) of 46.1 μM [1].</p>Formula:C21H23N7O2Purity:98%Color and Shape:SolidMolecular weight:405.45BI-0474
CAS:<p>BI-0474: KRASG12C inhibitor, IC50=7.0 nM, blocks GDP-KRAS/SOS1, anti-tumor in NCI-H358 cells & lung cancer model, for cancer research.</p>Formula:C30H37N9O2SPurity:99.61%Color and Shape:SolidMolecular weight:587.74FGTI-2734 mesylate (1247018-19-4 free base)
CAS:<p>FGTI-2734 mesylate hinders KRAS, overcoming resistance and targeting pancreatic tumors; inhibits FT and GGT with IC50s of 250 nM, 520 nM.</p>Formula:C27H35FN6O5S2Purity:98%Color and Shape:SolidMolecular weight:606.73(R)-VX-11e
CAS:<p>(R)-VX-11e is an isomer of VX-11e, a potent and selective ERK2 inhibitor with potential to inhibit tumor growth.</p>Formula:C24H20Cl2FN5O2Purity:98.73%Color and Shape:SolidMolecular weight:500.35KRAS G12C inhibitor 59
CAS:<p>KRAS G12C Inhibitor 59 is a compound with anticancer properties.</p>Formula:C32H39F6N7O5Purity:98%Color and Shape:SolidMolecular weight:715.69B-Raf IN 15
CAS:<p>B-Raf IN 15 is a BRAF inhibitor that inhibits BRAFWT and BRAFV600E and can be used to study melanoma and cancer.</p>Formula:C19H15N3OSPurity:98%Color and Shape:SolidMolecular weight:333.41KRAS G12C inhibitor 61
CAS:<p>KRAS G12C inhibitor 61 (Example 3) demonstrates potent activity by inhibiting phospho-ERK 1/2 in MIA PaCa-2 cells, reflected in an IC50 value of 9 nM.</p>Formula:C31H33ClFN7O2Purity:98%Color and Shape:SolidMolecular weight:590.09MNK inhibitor 9
CAS:<p>MNK inhibitor 9 potently blocks MNK1/2 (IC50: 0.003 µM each), is cell-permeable, and useful for tumor research.</p>Formula:C25H29N9OColor and Shape:SolidMolecular weight:471.56DL-threo dihydrosphingosine
CAS:<p>DL-threo dihydrosphingosine blocks ERK, inhibits smooth muscle proliferation, and works against growth factor/G-protein ERK activation.</p>Formula:C18H39NO2Color and Shape:SolidMolecular weight:301.51KRAS inhibitor-11
<p>KRAS inhibitor-11 is a KRAS inhibitor .</p>Formula:C29H47N9O6Color and Shape:SolidMolecular weight:617.74KRAS G12C inhibitor 1R
CAS:<p>KRAS G12C inhibitor 1R can be used in studies about Ras.</p>Formula:C31H36ClFN6O2Color and Shape:SoildMolecular weight:579.11GGTI-297
CAS:<p>GGTI-297 is a potent, cell-permeable, and selective peptidomimetic inhibitor of GGTase I compared to Farnesyl Transferase (FTase).</p>Formula:C26H31N3O3SColor and Shape:SolidMolecular weight:465.61Raf inhibitor 3
CAS:<p>Raf inhibitor 3 (Example 30), a potent inhibitor of both B-Raf and C-Raf, exhibits IC50 values below 15 nM. It is applicable in cancer research studies [1].</p>Formula:C18H19FN8O2SPurity:98%Color and Shape:SolidMolecular weight:430.46KRAS inhibitor-14
CAS:<p>KRAS inhibitor-14 targets G12C (IC50: 0.249 μM) and inhibits p-ERK in cancer cells; promising for pancreatic, colorectal, lung cancers.</p>Formula:C20H15Cl3FN3O2SColor and Shape:SolidMolecular weight:486.77Inflachromene
CAS:<p>Inflachromene (ICM) is an inhibitor of HMGB1 and HMGB expression with anti-inflammatory activity.Inflachromene is used in the study of epilepsy.</p>Formula:C21H19N3O4Purity:97.36% - 99.88%Color and Shape:SolidMolecular weight:377.39Laxiflorin B
CAS:<p>Laxiflorin B, a novel selective inhibitor of ERK 1/2 derived from herbal sources, exhibits antitumor activity [1].</p>Formula:C20H24O5Purity:98%Color and Shape:SolidMolecular weight:344.4HPK1-IN-13
CAS:<p>HPK1-IN-13 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.</p>Formula:C25H24FN5O2Color and Shape:SolidMolecular weight:445.49Glecirasib
CAS:<p>Glecirasib (JAB-21822,KRAS G12C inhibitor 36) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits KRAS G12C-dependent signaling</p>Formula:C31H26ClF4N7O2Purity:99.7% - >99.99%Color and Shape:SolidMolecular weight:640.03GSK1790627
CAS:<p>GSK1790627, the N-deacetylated metabolite of Trametinib, represents an orally active MEK inhibitor that promotes autophagy and triggers apoptosis [1].</p>Formula:C24H21FIN5O3Color and Shape:SolidMolecular weight:573.36SOS1-IN-5
CAS:<p>SOS1-IN-5, a potent pyrimidine inhibitor, disrupts RAS-SOS1, blocking KRAS activation.</p>Formula:C26H31F3N4O5Color and Shape:SolidMolecular weight:536.54ZG1077
CAS:<p>ZG1077, a covalent KRAS G12C inhibitor, is utilized in non-small cell lung cancer (NSCLC) research.</p>Formula:C33H33F2N5O5SColor and Shape:SolidMolecular weight:649.71KRAS G12C mutant protein inhibitor A-1
CAS:<p>KRAS G12C mutant protein inhibitor A-1 can be used in studies about Ras.</p>Formula:C31H26ClF4N7O2Color and Shape:SolidMolecular weight:640.03ERK1/2 inhibitor 9
CAS:<p>ERK1/2 Inhibitor 9 (Probe 1), a covalent antagonist of ERK1/2, exhibits sub-micromolar efficacy in cellular assays (A375 GI50=0.47 μM) and facilitates the</p>Formula:C31H32ClN7O3Purity:98%Color and Shape:SolidMolecular weight:586.08Org OD 02-0
CAS:<p>10-Ethenyl-19-norprogesterone (Org OD 02-0) is a selective agonist for the membrane progesterone receptor α (mPRα) with an IC50 of 33.9 nM, known to activate</p>Formula:C22H30O2Purity:98%Color and Shape:SolidMolecular weight:326.47FGTI-2734
CAS:<p>FGTI-2734, a dual FT/GGT-1 inhibitor (IC50: 250/520 nM), blocks KRAS membrane binding and curbs KRAS-driven pancreatic cancer.</p>Formula:C26H31FN6O2SPurity:99.69%Color and Shape:SolidMolecular weight:510.63GNE 220
CAS:<p>GNE-220 is a potent and selective inhibitor of MAP4K4 (IC50: 7 nM).</p>Formula:C25H26N8Purity:98%Color and Shape:SolidMolecular weight:438.53HPK1-IN-12
CAS:<p>HPK1-IN-12 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.</p>Formula:C25H24FN5O2Color and Shape:SolidMolecular weight:445.49XRP44X
CAS:<p>XRP44X (XRP 44X) is a potent inhibitor of Ras-Net (Elk-3) pathway.</p>Formula:C21H21ClN4OPurity:99.67%Color and Shape:SolidMolecular weight:380.87KRAS G12D mutation regulator 4
CAS:<p>KRAS G12D mutation regulator 4 can be used in studies about Ras.</p>Formula:C33H33FN6O2Color and Shape:SolidMolecular weight:564.65ERK-IN-2 free base
CAS:<p>ERK-IN-2 free base inhibits ERK2 (IC50: 1.8 nM); potential off-target effects at >10 μM.</p>Formula:C16H17N5O2Color and Shape:SolidMolecular weight:311.34DT-061
CAS:<p>DT-061 is an orally bioavailable protein phosphatase 2A (PP2A) activator. It could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis.</p>Formula:C25H23F3N2O5SPurity:98%Color and Shape:SolidMolecular weight:520.52KRAS G12C inhibitor 16
CAS:<p>KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor.</p>Formula:C24H21ClFN3O3Purity:97.84%Color and Shape:SolidMolecular weight:453.89CXJ-2
CAS:<p>CXJ-2, a cyclic peptide, binds EDPs, inhibits PI3K/ERK, and reduces hepatic cell growth/migration, offering antifibrotic effects.</p>Formula:C55H87N15O22Purity:98%Color and Shape:SolidMolecular weight:1310.37KRAS G12C inhibitor 58
CAS:<p>KRAS G12C inhibitor 58 is utilized in cancer research as an inhibitor of the KRAS G12C mutation [1].</p>Formula:C51H64ClF4N9O8SPurity:98%Color and Shape:SolidMolecular weight:1074.62HPK1-IN-27
CAS:<p>HPK1-IN-27 inhibits HPK1 (MAP4K1), a kinase with potential for cancer treatment, per patent WO2019016071A1, compound 38.</p>Formula:C26H23F3N4O4Color and Shape:SolidMolecular weight:512.48KRAS inhibitor FB9
CAS:<p>KRAS inhibitor FB9 can be used in studies about Ras.</p>Formula:C23H21ClF4N2O5Color and Shape:SolidMolecular weight:516.87KRAS G12D modulator-1
CAS:<p>KRAS G12D modulator-1 (compound 6), a potent modulator of KRAS G12D, exhibits IC50 values ranging from 1-10 μM against NEA-G12D, PPI-G12D, and p ERK-AGS, and is</p>Formula:C30H36FN5O4Purity:98%Color and Shape:SolidMolecular weight:549.64MS934
CAS:<p>MS934, a novel VHL-recruiting MEK 1/2 degrader, exhibits potent anti-proliferative effects on HT-29 cell growth, achieving a GI50 of 0.023 μM.</p>Formula:C52H69F3IN7O6SPurity:98%Color and Shape:SolidMolecular weight:1104.11B-Raf IN 16
CAS:<p>B-Raf IN 16, a BRAF inhibitor, belongs to cyclic iminopyrimidine derivatives and can be used for cancer or tumour research.</p>Formula:C20H19N5O3SPurity:99.31% - 99.78%Color and Shape:SolidMolecular weight:409.46pan-KRAS-IN-2
CAS:<p>Pan-KRAS-IN-2 (compound 6) is a broad-spectrum KRAS inhibitor exhibiting potent activity with IC50 values of ≤10 nM against KRAS wild type and its mutants (G12D</p>Formula:C34H34F2N4O3Purity:98%Color and Shape:SolidMolecular weight:584.66SB-682330A
CAS:<p>SB-682330A is a Raf kinase inhibitor.</p>Formula:C28H27N3O3Color and Shape:SolidMolecular weight:453.53TC13172
CAS:<p>TC13172 is a potent, covalent MLKL inhibitor, selective over RIPK1/RIPK3. It blocks TSZ-induced necroptosis (EC50=2nM) and MLKL oligomerization at 100nM.</p>Formula:C17H16N4O5SPurity:98%Color and Shape:SolidMolecular weight:388.4KRAS degrader-1
CAS:<p>KRAS degrader-1 (compound 1) is a potent agent that selectively targets KRAS proteins for destruction via the autophagy-lysosomal degradation pathway [1].</p>Formula:C55H57Br2ClFIN8O7Color and Shape:SolidMolecular weight:1283.25Cobimetinib racemate
CAS:<p>Cobimetinib racemate (Cobimetinib (racemate)) (GDC-0973 racemate) is a selective inhibitor of MEK.Cobimetinib racemate is also known as a mitogen-activated</p>Formula:C21H21F3IN3O2Purity:98.00% - 99.71%Color and Shape:SolidMolecular weight:531.31Kras binder 12
CAS:<p>Kras binder 12 can be used in studies about Ras.</p>Formula:C29H47N9O6Color and Shape:SoildMolecular weight:617.74ARQ-736
CAS:<p>ARQ 736 effectively targets and inhibits BRAF, crucial in MAPK pathway, beneficial for treating melanomas and certain colon cancers.</p>Formula:C25H25N8Na2O8PSColor and Shape:SolidMolecular weight:674.54Ilaprazole sodium hydrate
CAS:<p>Ilaprazole sodium hydrate (IY-81149 sodium hydrate) is a proton pump inhibitor that blocks the transport of HSV particles.</p>Formula:C19H21N4NaO4SPurity:99.2%Color and Shape:SolidMolecular weight:424.45KRAS G12C inhibitor 17
CAS:<p>KRAS G12C inhibitor 17 is a potent KRAS G12C inhibitor.</p>Formula:C24H20ClF2N3O3Purity:98%Color and Shape:SolidMolecular weight:471.88ARS-1323-alkyne
CAS:<p>ARS-1323-alkyne is a switch-II pocket (S-IIP) inhibitor and a conformational specific chemical reporter of KRASG12C nucleotide state in living cells.</p>Formula:C28H27ClF2N6O3Purity:98.00% - 99%Color and Shape:SolidMolecular weight:569ERK1/2 inhibitor 5
CAS:<p>ERK1/2 inhibitor 5: potent against ERK1/2, may combat cancer and inflammation.</p>Formula:C28H32ClFN6O5Color and Shape:SolidMolecular weight:587.04ARS-1323
CAS:<p>ARS-1323 is the racemate of ARS-1620 and a mutant K-ras G12C inhibitor.</p>Formula:C21H17ClF2N4O2Purity:99.53%Color and Shape:SolidMolecular weight:430.84KRAS G12C inhibitor 32
CAS:<p>KRAS G12C Inhibitor 32, an eight-membered heterocyclic compound with nitrogen, acts as a potent inhibitor of KRAS G12C [1].</p>Formula:C29H30Cl3FN6O3Purity:98%Color and Shape:SolidMolecular weight:635.94TH-Z827
CAS:<p>TH-Z827 is a mutant-selective inhibitor targeting KRAS(G12D) with an IC50 of 2.4 μM, demonstrating specificity by not binding to KRAS(WT) or KRAS(G12C).</p>Formula:C30H38N6OPurity:98%Color and Shape:SolidMolecular weight:498.66HPK1-IN-9
CAS:<p>HPK1-IN-9: Potent MAP4K family kinase inhibitor targeting hematopoietic progenitor cells; potential in HPK1 diseases. (Patent WO2021213317A1)</p>Formula:C30H33N7O2Color and Shape:SolidMolecular weight:523.63CHI-000-667
CAS:<p>CHI-000-667 can be used in studies about Ras.</p>Formula:C21H16ClNO4SColor and Shape:SolidMolecular weight:413.87KRAS G12C inhibitor 28
CAS:<p>KRAS G12C Inhibitor 28 is a compound that effectively inhibits the KRAS G12C mutation, exhibiting potent antitumor effects with an inhibitory concentration (</p>Formula:C33H36F2N5O4PColor and Shape:SolidMolecular weight:635.64K-Ras G12C-IN-2
CAS:<p>K-Ras G12C-IN-2 is a covalent kras g12c inhibitor.</p>Formula:C21H27ClN4O3Purity:98%Color and Shape:SolidMolecular weight:418.92SHP2-IN-22
CAS:<p>SHP2-IN-22, a potent SHP2 allosteric inhibitor, exhibits an IC50 value of 17.7 nM and effectively suppresses proliferation, migration, and invasion in MIA PaCa-</p>Formula:C23H22Cl2N8OColor and Shape:SolidMolecular weight:497.38KRAS G12C inhibitor 40
CAS:<p>KRAS G12C inhibitor 40 targets KRAS G12C in cancer research (WO2021129824A1, compound 70).</p>Formula:C34H36ClFN10O2Color and Shape:SolidMolecular weight:671.17HPK1 antagonist-1
CAS:<p>HPK1 antagonist-1 (I-792) is an inhibitor targeting HPK1, with potential applications in cancer and immune disease research [1].</p>Formula:C28H29FN6O2Color and Shape:SolidMolecular weight:500.57Exarafenib
CAS:<p>Exarafenib (RAF/KIN_2787) is an oral pan-RAF inhibitor with antitumor properties, targeting MAPK signaling in cancer research.</p>Formula:C26H34F3N5O3Purity:98.36% - 99.84%Color and Shape:SolidMolecular weight:521.58Kras4B G12D-IN-1
CAS:<p>Kras4B G12D-IN-1 is an inhibitor of Kras4B G12D with anticancer activity.Kras4B G12D-IN-1 inhibits Kras protein expression.</p>Formula:C16H21ClN2O4SPurity:99.75%Color and Shape:SolidMolecular weight:372.87HG6-64-1
CAS:<p>HG6-64-1 (HMSL 10017-101-1, compound 9 (XI-1)) is a potent and selective B-Raf inhibitor with an IC50 = 0.09 μM in B-raf V600E-transformed Ba/F3 cells.</p>Formula:C32H34F3N5O2Purity:99.89%Color and Shape:SolidMolecular weight:577.64ZYF0033
CAS:<p>ZYF0033(HPK1-IN-22) is an orally effective inhibitor of HPK1 that inhibits the phosphorylation of MBP proteins and decreases the phosphorylation of SLP76.</p>Formula:C26H30N4O2SPurity:99.70%Color and Shape:SolidMolecular weight:462.61JWG-071
CAS:<p>JWG-071: First ERK5 kinase probe, BET inhibitor, 1 μM BRD4 IC, boosts ERK5 function and BRD4 selectivity.</p>Formula:C34H44N8O3Purity:98.33%Color and Shape:SolidMolecular weight:612.77BI-2493
CAS:<p>BI-2493 is a highly selective pan-KRAS inhibitor and structural analog of BI-2865.BI-2493 exhibits antitumor activity and inhibits tumor cell growth.Cost-effective and quality-assured.</p>Formula:C24H27N7OSPurity:97.74% - 99.88%Color and Shape:SoildMolecular weight:461.58Pan-RAS-IN-1
CAS:<p>Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors.</p>Formula:C36H41Cl2F3N6O2Purity:99.77%Color and Shape:SolidMolecular weight:717.65MK-8353
CAS:<p>MK-8353 (SCH900353) is a potent, selective and orally available inhibitor of ERK1/2 (IC50s of 23.0 nM and 8.8 nM, respectively)</p>Formula:C37H41N9O3SPurity:96.15% - 97.19%Color and Shape:SolidMolecular weight:691.84KRAS G12C inhibitor 50
CAS:<p>KRAS G12C inhibitor 50 is a KRAS G12C inhibitor (IC50: 46.7 nM).</p>Formula:C31H34N8O2Color and Shape:SolidMolecular weight:550.65MK2-IN-4
CAS:<p>MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor (IC50: 45 nM). MK2-IN-4 can be used in cancer, inflammation and immunology studies.</p>Formula:C25H24N4O2Color and Shape:SolidMolecular weight:412.48KRAS inhibitor-36
CAS:<p>KRAS inhibitor-36 (compound Abd2) directly inhibits KRAS Q61H.</p>Formula:C14H13NO4Color and Shape:SolidMolecular weight:259.26KRASG12C IN-12
CAS:<p>KRASG12C IN-12 (compound-1) acts as an inhibitor of KRASG12C. It forms a ternary complex with intracellular CYPA and the activated mutant of KRASG12C.</p>Formula:C29H39N5O6S2Color and Shape:SolidMolecular weight:617.78KRAS G12D inhibitor 19
CAS:<p>KRAS G12D inhibitor 19 (Compound 7) is used in cancer research [1]. As a specific inhibitor of KRAS G12D, it targets and potentially suppresses this mutation, which is frequently associated with various cancers.</p>Formula:C35H34F2N6O3Color and Shape:SolidMolecular weight:624.68AZD4625
<p>AZD4625 (Compound 21) is a selective, potent, orally active, covalent and mutagenic mutant GTPaseKRASG12C inhibitor.</p>Formula:C24H21ClF2N4O3Color and Shape:SolidMolecular weight:486.9KRAS ligand 3
CAS:<p>KRAS ligand 3 (compound 1), a BTX-6654 target-binding ligand, exhibits synergistic tumor growth inhibition through its capacity to bind a KRAS inhibitor [1].</p>Formula:C24H28F3N5Color and Shape:SolidMolecular weight:443.51PAT-IN-1
CAS:<p>PAT-IN-1, a protein acyl transferases (PAT) inhibitor, competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) [1].</p>Formula:C45H68N4OColor and Shape:SolidMolecular weight:681.05KRAS G12C inhibitor 46
CAS:<p>KRAS G12C inhibitor 46 is a potent inhibitor of KRAS G12C.</p>Formula:C32H33F2N7O2Color and Shape:SolidMolecular weight:585.65Calderasib
CAS:<p>Calderasib (MK-1084) is a selective KRAS G12C inhibitor (IC50 1.2 nM) with anticancer activity, usable as monotherapy or combined with PD-1 inhibitors</p>Formula:C32H31ClF2N6O4Purity:98.69%Color and Shape:SolidMolecular weight:637.08BBO-8520
CAS:<p>BBO-8520 is a dual KRASG12C inhibitor that blocks ON and OFF states, disables effector binding, suppresses signaling, and induces tumor regression.</p>Formula:C35H33F6N7O2SPurity:97.879%Color and Shape:SolidMolecular weight:729.74KRAS inhibitor-35
CAS:<p>KRAS inhibitor-35 (compound 72) is a KRAS inhibitor with an IC50 of 2 nM, utilized in tumor research.</p>Formula:C38H32F4N6O3SColor and Shape:SolidMolecular weight:728.76COTI-219
CAS:<p>COTI-219 is an oral inhibitor of KRAS with antitumor properties [1].</p>Formula:C17H18N6SColor and Shape:SolidMolecular weight:338.43pan-KRAS-IN-6
CAS:<p>Pan-KRAS-IN-6 (compound 12) is a potent pan-KRAS inhibitor, with IC50 values of 9.79 nM for Kras G12D and 6.03 nM for Kras G12V.</p>Formula:C29H30ClF3N6O3SColor and Shape:SolidMolecular weight:635.10KRASG12D-IN-3-d3
CAS:<p>KRASG12D-IN-3-d3 is the deuterium labeled KRASG12D-IN-3. KRASG12D-IN-3 (compound Z1084) is a KRASG12D inhibitor with oral bioactivity that can effectively inhibit the growth of tumor cells AGS and AsPC-1, with IC50 values of 0.38 nM and 1.23 nM, respectively.</p>Formula:C31H27D3ClF6N7O2Color and Shape:SoildMolecular weight:685.08KRAS inhibitor-21
CAS:<p>KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor (IC50<0.01 μM) that can be used in cancer research.</p>Formula:C33H41N5O3Color and Shape:SolidMolecular weight:555.71Everafenib
<p>Everafenib: potent BRAF inhibitor, crosses blood-brain barrier, hinders MAPK, effective on V600EBRAF cells, outperforms other drugs in trials.</p>Formula:C20H23ClFN5O2S2Color and Shape:SolidMolecular weight:484.01Famlasertib
CAS:<p>Famlasertib is a potent inhibitor of the mitogen-activated protein kinase kinase kinase kinase (MAP4K) family, capable of penetrating the brain. It exhibits an IC50 value of 0.3 nM for HGK (MAP4K4) and 23.7 nM for MLK3.</p>Formula:C26H27ClN4OColor and Shape:SolidMolecular weight:446.972TH-Z816
CAS:<p>TH-Z816 acts as a reversible inhibitor targeting the KRAS(G12D) mutation, exhibiting an IC50 of 14 µM. This compound is utilized in cancer research [1].</p>Formula:C29H38N6OColor and Shape:SolidMolecular weight:486.65G12Si-1
<p>G12Si-1 selectively binds and inhibits K-Ras(G12S) to block oncogenic signaling and nucleotide exchange.</p>Formula:C29H32ClN5O3Color and Shape:SolidMolecular weight:534.05HPK1-IN-41
CAS:<p>HPK1-IN-41 (compound Z389) functions as an HPK1 inhibitor, exhibiting an IC50 value of 0.21 nM [1].</p>Formula:C28H33N5O2Color and Shape:SolidMolecular weight:471.59(+)-Perillyl alcohol
CAS:<p>(+)-Perillyl alcohol (0.25-1 mM) inhibits cell growth in SW480 cells. At a concentration of 1 mM and a duration of 24 hours, (+)-Perillyl alcohol increases the number of cells in the G0/G1 phase and reduces the number in the S phase in SW480 cells.</p>Formula:C10H16OColor and Shape:SolidMolecular weight:152.23MAP855
CAS:<p>MAP855: potent, selective, oral MEK1/2 inhibitor; IC50=3 nM, pERKEC50=5 nM; effective on wild-type/mutant MEK1/2.</p>Formula:C28H23ClF2N6O3Color and Shape:SolidMolecular weight:564.97MBA-m1
CAS:<p>MBA-m1 is an MLKL inhibitor that suppresses necroptosis in Mlkl−/−NIH-3T3 cells. Additionally, MBA-m1 alleviates disease conditions in mouse models of dermatitis and abdominal aortic aneurysm induced by MLKL.</p>Formula:C27H21ClN2O2Color and Shape:SolidMolecular weight:440.92ZCL279
CAS:<p>ZCL279 is a small molecule modulator (SMM) that inhibits the interaction between CDC42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 activates Cdc42, a cytoplasmic small GTPase in the Ras superfamily, while at higher concentrations (<10 μM) it significantly inhibits it.</p>Formula:C24H18N2O7S2Color and Shape:SolidMolecular weight:510.539Anti-osteoporosis agent-11
CAS:<p>Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. It exhibits its most prominent effect by inhibiting osteoclast differentiation, with an IC50 value of 0.36 μM. Additionally, Anti-osteoporosis agent-11 suppresses osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking the RANKL-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways.</p>Formula:C23H17NO2Se2Color and Shape:SolidMolecular weight:497.31KRAS G12D inhibitor 28
CAS:<p>KRAS G12D inhibitor 28 (Compound 1) is an inhibitor of KRAS G12D and can be utilized in cancer research.</p>Formula:C35H32Cl2FN5OColor and Shape:SolidMolecular weight:628.57MLKL-IN-1
<p>MLKL-IN-1 is a covalent inhibitor of MLKL with a Kd value of 50 μM.</p>Formula:C19H20N2O3Color and Shape:SolidMolecular weight:324.37INCB159020
CAS:<p>INCB159020 is an orally active inhibitor of KRAS G12D, exhibiting a KRAS G12D SPR value of 2.2 nM. It demonstrates anti-tumor activity.</p>Formula:C37H35ClFN7O2Color and Shape:SolidMolecular weight:664.171GDC-6036-NH
CAS:<p>GDC-6036-NH is a precursor of compound 17a /b, which is a RAS inhibitor that can be used in cancer research.</p>Formula:C26H30ClF4N7OPurity:99.84%Color and Shape:SolidMolecular weight:568.01KRAS inhibitor-13
CAS:<p>KRAS inhibitor-13 blocks KRAS G12C (IC50: 0.883 μM) and p-ERK in some cancer cells; promising for pancreatic, colorectal, lung cancer research.</p>Formula:C25H19ClFN3O2SColor and Shape:SolidMolecular weight:479.95HPK1-IN-42
CAS:<p>HPK1-IN-42 (compound 185) is an inhibitor of HPK1, displaying potent activity with an IC50 of 0.24 nM [1].</p>Formula:C26H30N6OSColor and Shape:SolidMolecular weight:474.62AMG-548 hydrochloride
<p>AMG-548 hydrochloride: orally active, p38α inhibitor (Ki=0.5 nM), 1000x less for p38γ/δ, also blocks TNFα (IC50=3 nM) & inhibits casein kinase 1 δ/ε.</p>Formula:C29H28ClN5OColor and Shape:SolidMolecular weight:498.02SHR902275
CAS:<p>SHR902275: potent RAF inhibitor, hits RAS mutations, oral use. cRAF IC50=1.6 nM, bRAFwt IC50=10 nM, bRAFV600E IC50=5.7 nM, hinders cell growth.</p>Formula:C26H23F3N4O4Color and Shape:SolidMolecular weight:512.48JD123
CAS:<p>JD123 inhibits the activity of JNK1 and the expression of cJun (1-135). It is an ATP-competitive inhibitor specific to p38-γ MAPK and has no effect on ERK1, ERK2, p38-α, p38-β, and p38-δ.</p>Formula:C12H11N5S2Color and Shape:SolidMolecular weight:289.379ERK1/2 inhibitor 6
CAS:<p>ERK1/2 inhibitor 6 - potent cancer/inflammation treatment from WO2021063335A1.</p>Formula:C27H29ClFN7O5Color and Shape:SolidMolecular weight:586.01RSK4-IN-1
CAS:<p>RSK4-IN-1 is a compound exhibiting potent inhibition of RSK4, demonstrated by an IC50 value of 9.5 nM.</p>Formula:C19H20F2N4O3Color and Shape:SolidMolecular weight:390.38HPK1-IN-3
<p>HPK1-IN-3: Selective HPK1 inhibitor, ATP-competitive, IC50=0.25nM; boosts IL-2 in PBMCs, EC50=108nM.</p>Formula:C23H22F4N6O2Color and Shape:SolidMolecular weight:490.45SOS1-IN-9
<p>SOS1-IN-9 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 116.5 nM).</p>Formula:C22H28F3N5OColor and Shape:SolidMolecular weight:435.49KRAS inhibitor-41
CAS:<p>KRAS inhibitor-41 is a KRAS inhibitor with an IC50 value of less than 0.01 μM for both KRAS G12D and KRAS G12V mutations. It effectively inhibits RAS mutant cell lines GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 is applicable for cancer research.</p>Formula:C30H37FN10OSColor and Shape:SolidMolecular weight:604.745KRAS G12C inhibitor 44
<p>KRAS G12C inhibitor 44: potent, oral, anti-cancer; halts cell growth in MIA PaCA-2, H358; effective in vivo. IC50: MIA-0.016μM, H358-0.028μM.</p>Formula:C31H36ClFN6O2Color and Shape:SolidMolecular weight:579.11Rho GTPase inhibitor 1
CAS:<p>Rho GTPase inhibitor 1 (compound 7) is a potent inhibitor of Rho GTPase. It exhibits high affinity for Cdc42, Rac1, and RhoA, with dissociation constants (KDs) of 151 μM, 352 μM, and 232 μM, respectively. Additionally, Rho GTPase inhibitor 1 reduces cell migration in glioblastoma cell lines.</p>Formula:C18H16N2OColor and Shape:SolidMolecular weight:276.33MEK4 inhibitor-2
CAS:<p>MEK4 Inhibitor-2, a novel MEK4 inhibitor, demonstrates efficacy against pancreatic adenocarcinoma, exhibiting an IC50 value of 83 nM.</p>Formula:C20H15FN4O3SColor and Shape:SolidMolecular weight:410.42EBI-907
CAS:<p>EBI-907 is a potent, oral B-RafV600E inhibitor with an IC50 of 4.9 nM, over 10x stronger than Vemurafenib, and effective against key cancer kinases.</p>Formula:C23H21ClF2N4O3SColor and Shape:SolidMolecular weight:506.95L 739749
CAS:<p>L 739749 is a CAAX peptidomimetic. It is also an inhibitor of farnesyl-protein transferase.</p>Formula:C24H41N3O6S2Purity:98%Color and Shape:SolidMolecular weight:531.73LSN3074753
CAS:<p>LSN3074753, a derivative of LY3009120, acts as a pan-RAF and Raf dimer inhibitor. This compound exhibits inhibitory activity against tumor cells driven by either BRAF monomers or RAF dimers, particularly in the activation of the MAPK pathway, including colorectal cancers with BRAF or KRAS mutations. When combined with Cetuximab, LSN3074753 demonstrates additive and synergistic effects in colorectal cancer PDX models, especially in those harboring KRAS or BRAF mutations.</p>Formula:C24H30FN5O2Color and Shape:SolidMolecular weight:439.53Fulzerasib
CAS:<p>Fulzerasib is an orally active KRAS G12C inhibitor that covalently binds to cysteine residue on the protein, thereby inhibiting the growth of KRAS G12C mutant</p>Formula:C32H30ClFN6O4Purity:98.04%Color and Shape:SolidMolecular weight:617.07SOS1-IN-6
CAS:<p>SOS1-IN-6 (compound 33-P1) is a potent inhibitor of SOS1, acting on SOS1-G12D (IC50: 14.9 nM) and SOS1-G12V (IC50: 73.3 nM).</p>Formula:C26H28F3N3O2Color and Shape:SolidMolecular weight:471.51HPK1-IN-21
<p>HPK1-IN-21 is a potent, orally active HPK1 kinase inhibitor with a Ki value of 0.8 nM.</p>Formula:C22H25ClFN5O2Color and Shape:SolidMolecular weight:445.92Cot inhibitor-3
CAS:<p>Cot inhibitor-3 (Compound 33) is an effective and selective cancerosaka thyroid (COT) kinase inhibitor with an IC50 of 4 nM. It can be used to prevent limpness caused by inflammation.</p>Formula:C30H28N8OColor and Shape:SolidMolecular weight:516.60MEK1/2-IN-2
<p>MEK1/2-IN-2 is a potent, ATP-competitive MEK1/2 inhibitor that exhibits equal inhibitory effects on wild-type MEK1/2 and a group of MEK1/2 mutant cells.</p>Formula:C28H22ClFN6OColor and Shape:SolidMolecular weight:512.97BMS-214662
CAS:<p>BMS-214662 is a selective farnesyl transferase inhibitor with anti-tumor activity, used in research on pancreatic cancer, head and neck cancer, and lung cancer.</p>Formula:C25H23N5O2S2Purity:99.58% - 99.58%Color and Shape:SolidMolecular weight:489.61HPK1-IN-16
CAS:<p>HPK1-IN-16, a potent HPK1 inhibitor, useful for cancer research and treatment.</p>Formula:C28H27FN4OColor and Shape:SolidMolecular weight:454.54HPK1-IN-31
<p>HPK1-IN-31 inhibitor with an IC 50 value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunotherapy .</p>Formula:C30H33N7O3Color and Shape:SolidMolecular weight:539.63AMG-548 dihydrochloride
<p>AMG-548 dihydrochloride, an oral p38α inhibitor (Ki: 0.5 nM), selectively targets p38β, γ, δ, inhibits TNFα (IC50: 3 nM), and suppresses Wnt signaling.</p>Formula:C29H29Cl2N5OColor and Shape:SolidMolecular weight:534.48K-Ras-IN-4
CAS:<p>K-Ras-IN-4 (compound CP163) is an inhibitor of K-Ras.</p>Formula:C31H28F4N6O3SColor and Shape:SolidMolecular weight:640.65ERK2 IN-1
CAS:<p>ERK2 IN-1 is a selective ERK2 inhibitor with an IC50 of 7 nM.</p>Formula:C36H34FN7O2SPurity:98%Color and Shape:SolidMolecular weight:647.76HPK1-IN-30
CAS:<p>HPK1-IN-30 is a potent inhibitor of HPK1. HPK1-IN-30 has potential for cancer disease research.</p>Formula:C25H23FN6Color and Shape:SolidMolecular weight:426.49ATX inhibitor 26
CAS:<p>ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. It effectively inhibits cell migration and collagen gel contraction. Additionally, ATX inhibitor 26 demonstrates significant antifibrotic activity, reducing collagen deposition in a Bleomycin (BLM)-induced pulmonary fibrosis model.</p>Formula:C18H19Cl2N7O3Color and Shape:SolidMolecular weight:452.30VVD-699
CAS:<p>VVD-699 is a covalent inhibitor of RAS-PI3K. It forms a covalent bond with cysteine at position 242 within the RAS-binding domain of PI3Kp110α, thereby obstructing the ability of RAS to activate PI3K. VVD-699 is capable of inhibiting the growth of tumors with RAS mutations and HER2 overexpression. It is applicable in research related to RAS mutation-associated cancers, such as those involving H358 lung cancer cells, A549 cells, and FaDu cells.</p>Formula:C25H30ClFN2O6S2Color and Shape:SolidMolecular weight:573.097SHR2415
<p>SHR2415: Potent, selective ERK1/2 inhibitor, oral; ERK1 IC50: 2.8 nM, ERK2 IC50: 5.9 nM; effective in Colo205 (IC50: 44.6 nM), for cancer research.</p>Formula:C23H22ClN7O2Color and Shape:SolidMolecular weight:463.92HPK1-IN-55
CAS:<p>HPK1-IN-55 (compound 19) is a selective and orally active inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an IC50 of less than 0.51 nM. It exhibits exceptional kinase selectivity, being over 637 times more selective for HPK1 compared to GCK kinase and over 1022 times compared to LCK. HPK1-IN-55 possesses anti-cancer properties.</p>Formula:C30H34N8O3Color and Shape:SolidMolecular weight:554.643KRAS G12D inhibitor 3
CAS:<p>KRAS G12D Inhibitor 3, a compound targeting the KRAS G12D mutation, demonstrates potent antitumor efficacy with an inhibitory concentration (IC50) of less than</p>Formula:C34H31ClF3N5O2Color and Shape:SolidMolecular weight:634.09Sosimerasib
CAS:<p>Sosimerasib is an inhibitor of the kirsten rat sarcoma viral oncogene homolog (KRAS) and exhibits antitumor activity.</p>Formula:C36H39ClFN7O4Color and Shape:SolidMolecular weight:688.191MRTX849 ethoxypropanoic acid
CAS:<p>MRTX849 is a KRAS G12C ligand and PROTAC linker for creating potent LC-2, degrading KRAS G12C with DC50 of 0.25-0.76 μM.</p>Formula:C37H43ClFN7O5Color and Shape:SolidMolecular weight:720.24KRAS G12D inhibitor 12
<p>KRAS G12D inhibitor 12 targets Ras protein for cancer research. (Patent WO2021108683A1, Compound 134)</p>Formula:C23H21ClFN5O3Color and Shape:SolidMolecular weight:469.9ERK-IN-2
CAS:<p>ERK-IN-2, an ERK2 inhibitor, exhibits an IC50 value of 1.8 nM. At doses greater than 10 μM, it may induce off-target toxicity and/or activity [1].</p>Formula:C16H18ClN5O2Purity:98%Color and Shape:SolidMolecular weight:347.80SML-10-70-1
CAS:<p>SML-10-70-1 is a Novel Active Site Inhibitor of Oncogenic K-Ras G12C.</p>Formula:C25H42ClN7O13P2Color and Shape:SolidMolecular weight:746.04Dorrigocin A
CAS:<p>Dorrigocin A, an analog of Migrastatin, inhibits the carboxymethyltransferase involved in Ras processing, reversing the morphology of Ras-transformed NIH/3T3 cells. Dorrigocin A holds potential for research as an anticancer and anti-arthritis agent.</p>Formula:C27H41NO8Color and Shape:SolidMolecular weight:507.616SOF-436
CAS:<p>SOF-436 is a KRAS inhibitor that can suppress SOS1-mediated KRAS nucleotide exchange (IC50 = 60 μM) and inhibit the interaction between KRAS and the effector protein RAF. SOF-436 is applicable to cancer research.</p>Formula:C15H13F2NO4S2Color and Shape:SolidMolecular weight:373.395JAK3-IN-13
<p>JAK3-IN-13: Oral JAK3 inhibitor, selective & potent. Acts on NK1, JNK2, JNK3, Tyk2. Anti-tumor. IC50: JNK3, 8 nM; Tyk2, 365 nM; JNK2, 2039 nM; NK1, 4728 nM.</p>Formula:C25H33ClN6O5Color and Shape:SolidMolecular weight:533.02
